γδ T Cell and PARP Inhibitor Combination Therapy for Lower Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using PARP inhibitors are associated with toxicities such as nausea and fatigue, and there is a need for more effective immunotherapy strategies that can potentiate tumor killing while minimizing these side effects.
Innovation Solution
Combining γδ T cell immunotherapy with DDR inhibitors, such as PARP inhibitors, and potentially other immunotherapies like immune checkpoint blockade and chemotherapeutic agents, where γδ T cells are genetically modified to be resistant to chemotherapeutic agents, allowing for reduced doses of PARP inhibitors and enhanced tumor killing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PARP inhibitors are used to treat cancer, then tumor cell killing is enhanced, but toxicities such as nausea and fatigue increase
Solution Approach 1:
The patent combines γδ T cell immunotherapy with PARP inhibitor treatment to achieve synergistic tumor cell killing. The γδ T cells are genetically modified to express chemokine receptors that respond to CXCL12, enabling them to home to tumor sites where PARP inhibitors have created DNA damage. This combination allows reduced doses of PARP inhibitors while maintaining or enhancing efficacy, thereby reducing toxicities.
Solution Approach 2:
The patent uses CXCL12 chemokine signaling as an intermediary mechanism to guide γδ T cells to tumor sites. The genetically modified γδ T cells express CXCR4 receptors that bind to CXCL12, creating a directed trafficking system that concentrates immune cells at tumor locations where PARP inhibitors have induced DNA damage, enhancing local antitumor activity while reducing systemic toxicities.
2Reliability
If higher doses of PARP inhibitors are administered to enhance tumor killing, then treatment efficacy improves, but toxicities increase
Solution Approach 1:
The patent merges immunotherapy with targeted chemotherapy to achieve enhanced tumor killing at lower drug doses. The γδ T cells provide a biological amplification mechanism that reduces the need for high-dose PARP inhibitors, thereby maintaining treatment efficacy while minimizing toxicities.
Solution Approach 2:
The patent changes the dosing parameters of PARP inhibitors by using lower doses in combination with γδ T cell therapy. This parameter change is made possible by the synergistic effect of the combination therapy, where the immune cells compensate for the reduced drug dosage while maintaining or enhancing antitumor activity.
3Reliability
If γδ T cells are genetically modified to resist chemotherapeutic agents, then they can survive in the presence of chemotherapy, but device complexity increases
Solution Approach 1:
The patent applies local quality modification by introducing specific genetic traits (chemotherapy resistance and CXCR4 expression) only to the γδ T cells that need to survive in the chemotherapy environment and home to tumors. This localized genetic modification approach minimizes overall system complexity while achieving the desired functionality.
Solution Approach 2:
The patent creates composite γδ T cells with multiple genetic modifications combined in a single cell type. These composite cells simultaneously express chemotherapy resistance genes and CXCR4 chemokine receptors, integrating multiple functions into one therapeutic agent to reduce overall treatment complexity.
Data Source
AI summary
The invention provides combination therapies for treating cancer comprising compositions and methods for γδ T cell immunotherapy in combination DDR inhibitors, including but not limited to PARP inhibitors. Preferably, the combination of γδ T cell immunotherapy and PARP inhibitors for the treatment of cancer further includes combinations with other immunotherapies such as immune checkpoint (ICP) blockade therapy and/or DNA damaging agents such as cytotoxic chemotherapeutic agents. Preferably, when the combination of γδ T cell immunotherapy and DDR inhibitor therapy further include chemotherapeutic agents, the γδ T cells are genetically modified to impart resistance to that chemotherapeutic agent.